An enzyme competitive hybridization assay was developed and validated for determination of mouse plasma concentrations of a 15mer antisense phosphodiester oligodeoxyribonucleotide and of two phosphorothioate analogs. Assays were performed in 96-well microtiter plates. The phosphodiester sense sequence was covalently bound to the microwells. The 5′-biotinylated antisense sequence was used as tracer. The principle of the assay involves competitive hybridization of tracer and antisense nucleotide to the solid phase-immobilized sense oligonucleotide. Solid phasebound tracer oligonucleotide was assayed after reaction with a streptavidin-acetylcholinesterase conjugate, using the colorimetric method of Ellman. As in competitive enzyme immunoassays, coloration was inversely related to the amount of analyte initially present in the sample. The limit of quantification was 900 pM for phosphodiester antisense oligonucleotide using a 100 µl volume of plasma without extraction. Cross-reactivity was negligible after a four base deletion in either the 3′ or 5′ position. The assay was simple and sensitive, suitable for in vitro screening of oligonucleotide hybridization potency in biological fluids and for measuring the plasma pharmacokinetics of phosphorothioate and phosphodiester sequences.
INTRODUCTION
In recent years interest has grown in antisense oligonucleotides as therapeutic agents or pharmacological tools (1) (2) (3) . Their activity is based on interaction with specific mRNA and/or DNA and more precisely on complementary association between the antisense oligonucleotide and the sense nucleic acid (1) . For successful therapeutic use of antisense oligonucleotides their stability in biological fluids, target specificity and pharmacokinetic profiles must be optimized. However, only radiolabeling of currently available assays is sensitive enough for biological studies. Most pharmacokinetic profiles have been obtained using 32 P-, 35 S-or 3 H-radiolabeled oligonucleotides (4) (5) (6) (7) . This approach is cumbersome, expensive, calls for radiolabeling procedures that often result in decreasing drug purity and cannot be used easily for human experiments.
Nucleic acid hybridization has become a fundamental technique of molecular biology, but few analytical methods using this concept have been developed. In the diagnostic field the covalent immobilization of DNA in polystyrene microwells offers a very promising and convenient method (8) (9) (10) . In these approaches a complementary oligonucleotide sequence of DNA is covalently bound to the well surface and either a sandwich hybridization assay or competitive assay is performed for DNA determination with oligonucleotide tracer (8) . Chevrier et al. (8) evaluated the limit of quantification as 100 fmol/well with 5 µl DNA sample/well (20 nM) for competitive assay. The sandwich method was 30-fold more sensitive (0.7 nM).
Temsamani et al. (11) proposed a method based on hybridization properties for quantification of oligodeoxynucleotide phosphorothioates in biological fluids such as plasma and in tissues. The antisense oligonucleotide is immobilized on a nylon membrane and a labeled complementary oligonucleotide is used to quantitate the amount of fixed analyte. However, this method includes an inconvenient first step of solvent extraction. De Serres et al. (12) developed a competitive hybridization assay without extraction for determination of the plasma concentration of phosphorothioate antisense oligonucleotides. This assay involved competitive hybridization of unlabeled 15 base phosphorothioate antisense nucleic acid and a radiolabeled analog of a biotinylated complementary sense nucleic acid. Detection depended on a scintillation proximity assay with streptavidin-coated microspheres containing scintillant. However, this technique was expensive and of low sensitivity (limit of quantification ∼5 nM) for pharmacokinetic studies.
An assay based on hybridization constitutes a novel and promising approach to the measurement of antisense oligonucleotides in biological fluids, but a more convenient and sensitive method avoiding extraction procedures is required.
Inspired by our extensive experience with competitive enzyme immunoassays in 96-well microtiter plates, we applied this method to the development and validation of a simple and sensitive enzyme competitive hybridization assay for phosphodiester and phosphorothioate oligonucleotides in biological fluids, without any extraction procedure. We selected as models a 15mer antisense oligonucleotide directed against Friend retrovirus, which causes leukemia in mice, as well as two phosphorothioate analogs, because of their well-known nuclease resistance. In vitro screening *To whom correspondence should be addressed. Tel: +33 1 69 08 77 07; Fax: +33 1 69 08 59 07; Email: deverre@dsvidf.cea.fr Nucleic Acids Research, 1997, Vol. 25, No. 18 3585 of hybridization potency, plasma stability and preliminary pharmacokinetic profiles after i.v. administration to mice of these three compounds were used to demonstrate the usefulness of the method.
MATERIALS AND METHODS

Reagents
All oligonucleotides were synthesized by Eurogentec (Seraing, Belgium) (Table 1) . Oligo A is a 15 base phosphodiester deoxyribonucleotide which is complementary to the 5′-region of the initiation codon AUG of the Env mRNA from Friend retrovirus. The two phosphorothioate sequences selected have the same base sequence as oligo A, but with two internucleotide phosphorothioate linkages at the 3′-end (oligo 2-S-A) or all internucleotide phosphorothioate linkages (oligo all-S-A). The sense target, a 21mer phosphodiester deoxyribonucleotide, is composed of a 15mer complementary to oligo A plus a 6mer (AAA AAA) at the 5′-end, used as a spacer arm between the surface of the plate and oligo A. The tracer was 5′-biotinylated oligo A. 3′ and 5′ oligo A deletion oligomers (N-2, N-4 and N-6) were synthesized. Compounds K and KS were respectively 15 base phosphodiester and phosphorothioate deoxyribonucleotides and were selected arbitrarily because their sequence is different from that of oligo A and because they do not interfere in the assay. They were necessary to avoid non-specific adsorption of the phosphodiester or phosphorothioate sequence to the microwells. Table 1 . Sequences of the oligodeoxynucleotides tested and cross-reactivity coefficients measured in mouse plasma Blank mouse plasma was collected from OF 1 male mice (Charles River, Saint Aubin, France). The G4 form of acetylcholinesterase (AChE, EC 3.1.1.7) covalently bound to streptavidin was kindly provided by SPI-BIO (Massy, France) and was used as enzymatic reagent. Enzyme activities were measured as previously described for enzyme immunoassays (13) using Ellman's reagent, an AChE substrate consisting of 2.2 g acetylthiocholine and 1 g 5,5′-dithiobis-(2-nitrobenzoic acid) in 200 ml 0.05 M phosphate buffer, pH 7.4.
Assay buffer consisted of distilled water containing 0.75 M NaCl, 5 mM EDTA, 0.1% Tween 20, 10 µg/ml sheared, denatured herring sperm DNA, 1 µg/ml deoxyribonucleotide K and 5 × 10 -3 M phosphate buffer, pH 7.
Apparatus
Assays were performed in microtiter plates (Covalink NH modules; A/S Nunc, Polylabo, Strasbourg, France). Experiments were performed using an Autowash 96 microtiter plate washer (Labsystem, Helsinki, Finland), an Autodrop solution distributor (Titertek Flow Laboratories, Ayrshire, UK) and a Multiskan RC plate reader (Labsystem).
Coating of the plates
Deoxyribonucleotide A was covalently immobilized on the surface of wells of Covalink NH microplates as described by Rasmussen et al. (9) and Chevrier et al. (8) . The 5′-end terminal phosphate groups were grafted onto the polystyrene surface via amino groups using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide. Briefly, phosphorylated sense target was denatured by heating for 10 min at 95_C and was then immediately chilled on ice. Denatured phosphorylated sense target (5.5 nM in 100 µl cold 10 mM 1-methylimidazole buffer, pH 7) and 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide (770 µg in 20 µl cold 100 mM 1-methylimidazole buffer, pH 7) were added to each well. Plates were kept at +4_C until use.
Standard solution, preparation of control samples and plasma samples
Oligo A and phosphorothioate analogs were diluted first in water, then in blank mouse plasma heated for 15 min at 60_C and containing 10 µg/ml denatured herring sperm DNA, 5 mM EDTA and 1 µg/ml oligo K (or oligo KS) for phosphodiester assay (or phosphorothioate assay). Herring sperm DNA, EDTA and oligo K (or KS) were added to plasma samples or plasma control samples before assay to ensure that the media of the standard and samples were identical.
Competitive hybridization assay
The oligonucleotide tracer was diluted in assay buffer at a concentration of 55 pM. Before use the coated plates were washed with 0.01 M phosphate buffer, pH 7.4, containing 0.05% Tween 20 (washing buffer) using the Autowash apparatus (300 µl/well, 10 cycles) and stored on ice. The assay was performed in a total volume of 150 µl (50 µl tracer and 100 µl samples, standard or control). The plates were covered with plastic adhesive sheet and left for 15 min in a 60_C water bath, which was then switched off and the plates were left overnight in water. The plates were then washed as described above. Streptavidin-acetylcholinesterase conjugate (0.2 U/ml) was dispensed (100 µl) into each well. The plates were covered with a plastic adhesive sheet and left for 4 h at room temperature protected from light. They were washed again and Ellman's reagent (200 µl) was dispensed into each well using the Autodrop apparatus. During the enzymatic reaction the plates were protected from light. Absorbance at 414 nm was measured in each well after 4 h. All measurements for standards, control samples and samples were made in duplicate. Immunofit EIA/RIA (Beckman, CA) software with a four parameter logistic transformation was used for calibration and IC 50 measurement.
IC 50 is the concentration of analyte giving 50% of the signal achieved in the absence of analyte.
Validation procedure
The intra-and inter-assay accuracy and precision of the method were assessed from control samples which were included in each assay following the recommendations for analytical methods validation in pharmacokinetic studies (14) . Three concentrations of quality control samples were selected from the range covered by the assay according to the precision profile (Fig. 2B) . The quality control samples were aliquoted and stored frozen (-80_C) with plasma samples until assay. They were used to estimate the accuracy in the upper, middle and lower parts of the calibration curve, which corresponded to three different slopes. The concentrations of the control samples were determined for each assay and these data were accumulated over five assays.
The specificity of the competitive hybridization assay was assessed by comparing standard curves obtained with deoxyribonucleotide A to those obtained with oligo A-related oligomers deleted at the 3′-or 5′-end (N-2 to N-6) in mouse plasma. IC 50 values were used to evaluate the relative affinity of the tested sequence for the sense target. Results were expressed in terms of percentage cross-reactivity by dividing the IC 50 value for oligo A by the IC 50 for the tested oligomer and multiplying by 100. 'Cross-reactivity' is a term commonly used in the field of immunoanalysis (15) to measure the antibody response to substances other than the analyte. This term contrasts with 'assay specificity', which describes the ability of an antibody to produce a measurable response only for the analyte of interest. In a wider sense, considering the analogy between antigen-antibody reactions and sense-antisense hybridization, we use the term cross-reactivity to describe the ability of substances other than the analyte to hybridize to the immobilized sense sequence.
The limit of quantification was defined as the lower concentration of quality control samples of oligo A with a coefficient of variation (CV, calculated from intra-and inter-assay accuracy) <25%.
In vitro plasma stability
An aqueous solution (30 µl) containing oligo A (272 nM), oligo 2-S-A (272 nM) or oligo all-S-A (2.72 µM) was incubated with 270 µl 100% non-heat-inactivated blank mouse plasma at 37_C in a water bath. Two tests were performed for each deoxyribonucleotide (A, 2-S-A and all-S-A). At the indicated times (0, 5, 15, 30 and 60 min) a 50 µl fraction of each incubation solution was removed and added to 450 µl assay buffer. The samples were analyzed by the competitive hybridization assay as described above.
Animal studies
Oligo A, 2-S-A and all-S-A were injected at a dose of 120 nmol/kg via the tail vein into OF 1 male mice weighing ∼24 g. Animals were anesthetized by halothane at the indicated times (3, 6, 12 and 24 min). Blood was collected by abdominal vein puncture after halothane anesthesia. It was transferred to (5 mM) EDTA-coated collection tubes, centrifuged at +4_C to obtain plasma samples and stored frozen (-80_C) until assay. Three mice were used at each time point. Pharmacokinetic analysis was performed using SIPHAR software (SIMED SA, Créteil, France). Non-compartmental analysis gave a rough estimate of the half-life (T 1/2 ) and of the area under the plasma concentration-time curve (AUC) extrapolated to infinity. Plasma clearance (Cl) was calculated by dividing the dose by AUC.
RESULTS AND DISCUSSION
Analytical method
The aim of this work was to develop a competitive hybridization assay directly derived from the immunoenzymatic model by replacement of the antigen-antibody interaction by a sense-antisense oligonucleotide reaction. The principle of the method is illustrated in Figure 1 .
This principle was applied to measurement of plasma concentration of a 15mer phosphodiester oligonucleotide (oligo A) and of two modified sequences with phosphorothioate linkages (oligo 2-S-A and oligo all-S-A) using the same sense tracer. The hybridization could take place directly in plasma without any extraction procedure. Typical standard curves recorded in mouse plasma ( Fig. 2A) showed that there was competitive hybridization with target sense oligo A between the tracer and the three tested antisense sequences (oligo A, oligo 2-S-A and oligo all-S-A). As in competitive enzyme immunoassays, the colorimetric signal was inversely related to the amount of analyte present in the sample. Interestingly, using the same conditions the mouse plasma concentration of the sense target could be determined by this technique. Calibration curves (data not shown) were equivalent to those of oligo A. In this case there is competition between solid phase-immobilized sense target and soluble sense target for hybridization with the tracer. Signal intensities were measured after 10 min reaction with Ellman's reagent. Signal intensities were measured after 10 min reaction with Ellman's reagent and are expressed as percentages of the signal intensity at zero concentration.
Two parameters were identified as governing the sensitivity of the method: the concentration of sense target covalently linked to the microwells and the tracer concentration. To optimize these parameters experiments were conducted with or without oligo A and using various tracer concentrations (from 11 to 2200 pM) and Figure 1 . Principle of hybridization competitive assay. Assays were performed in 96-well plates. The sense target was covalently bound to the microtiter wells. 5′-Biotinylated oligo A was used as tracer. The assay involved competitive hybridization of tracer and antisense nucleotide to the solid phase-immobilized oligonucleotide. Solid phase-bound tracer oligonucleotide was measured after reaction with a streptavidin-acetylcholinesterase conjugate. After washing, solid phase-bound enzyme was measured using the colorimetric method of Ellman.
various concentrations of sense target (from 0 to 1000 nM) (Tables 2 and 3 ). In the absence of competitor oligo A the signal is proportional to the sense or tracer concentration ( Table 2 ). The same signal was observed for a 100 and a 1000 nM sense target concentration (Table 2 ). This could be related to saturation of the coupling site on the well surface. In the presence of oligo A a decrease in signal corresponds to an increase in assay sensitivity. The lower the concentration of sense target or tracer the greater the sensitivity of the method (Table 3) , but the longer the reaction period with Ellman's reagent to differentiate signal from background. In the light of these results, sense target and tracer concentrations were arbitrarily set at 5.5 and 55 pM respectively.
Validation parameters were assessed with three quality control samples in mouse plasma for each tested sequence (oligo A, oligo 2-S-A and oligo all-S-A) ( Table 4) . Acceptable intra-and inter-assay CV (<20%, 25% for lowest quality control concentration) were obtained in the range of calibration: 0.9-3.6, 0.2-1.8 and 4-36 nM for oligo A, oligo 2-S-A and oligo all-S-A respectively (Table 4) . Compared with the nominal value for each antisense quality control the results showed biases below 20% (25% for lowest quality control concentration). The specificity of the method was assessed in plasma by comparing the ability of oligo A and oligo A-related oligomers deleted at the 3′-or 5′-end to compete with tracer (see Materials and Methods and Table 1 ). Cross-reactivity of 3′ or 5′ N-2 deleted oligomers was 48%, whereas it was below 3% with N-4 and N-6 Precision profile corresponding to six calibration curves for each analyte. CVs were determined using back-calculated concentrations for each standard point using a four parameter logistic transformation.
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3′ or 5′ oligomers. These results are in total agreement with those described by de Serres et al. (12) with scintillation proximity competitive hybridization assay of a phosphorothioate antisense oligonucleotide in plasma. Concentrations determined by this assay are reported as intact oligo A (or 2-S-A or all-S-A). We assumed that these concentrations could be overestimated by the presence of N-1 or N-2 or perhaps N-3 metabolites. Work is in progress to quantify this overestimation. Nevertheless, our experiments demonstrated that these metabolites were able to hybridize with the sense target in biological fluid (plasma) and hence, like oligo A, they should be endowed with pharmacological activity. In a sense our test could be considered as measuring the total 'hybrido-reactivity' of the sample, which is very likely closely related to the biological activity of the oligonucleotide.
Application
In vitro screening of oligonucleotide hybridization potency. The ability of various unrelated sequences to hybridize with the sense target was evaluated using the hybridization competitive assay in a biological fluid (mouse plasma) by determining cross-reactivity coefficient (see Materials and Methods and Table 1 ). As expected, oligo K (or KS), whose sequence is not complementary with the sense target or antisense oligo A, was very poorly recognized by the assay (cross-reactivity <0.2). The phosphorothioate deoxyribonucleotide with all internucleotide phosphorothioate linkages (oligo all-S-A) was a weak competitor, with a cross-reactivity of 6%. It is very likely that this is at least partly due to the lower affinity of the phosphorothioate chimera (T m < T m of phosphodiester oligo A) for the sense target. Under these conditions competition is not favored and it would be interesting to use a phosphorothioate tracer which may increase (but not obligatorily) assay sensitivity. Surprisingly, the best competitor was phosphorothioate deoxyribonucleotide 2-S-A, with two internucleotide phosphorothioate linkages at the 3′-end, which showed 154% cross-reactivity. It is thus detected more sensitively than oligo A, which is entirely composed of phosphodiester bonds. This result is rather puzzling because oligo A is supposed to have a greater affinity for the immobilized sense sequence. However, it is worth noting that the standard curves established in mouse plasma not only reflect the hybridization potency of antisense oligonucleotide but may also be influenced by protein binding, oligo degradation and other uncharacterized interactions. Some of these interactions may be responsible for the difference observed between oligo A and oligo 2-S-A.
In vitro stability. The hybridization competitive assay was used to examine the stability of the three tested compounds in mouse plasma (Fig. 3) . Oligo A was degraded in mouse plasma [>85% in 1 h, apparent half-life (T 1/2 ) ∼30 min]. Addition of 5 mM EDTA prevented degradation. Using HPLC analysis and radioactive nucleic acids, Sands et al. (16) observed the same half-life for a 20 base phosphodiester sequence.
Phosphorothioate sequences (oligo S-A or oligo all-S-A) were more stable in mouse plasma, with an apparent T 1/2 of ∼1 h. In contrast, Sands et al. (16) noted no degradation of a phosphorothioate 20mer sequence in mouse plasma. This discrepancy concerning in vitro stability of phosphorothioates has been observed before and explained by Crooke et al. (17) as a consequence of nuclease inhibition by phosphorothioate. Our in vitro stability studies were performed with phosphorothioate plasma concentrations 4 (oligo all-S-A) to 40 (oligo 2-S-A) times lower than those used by Sands et al. (16) .
Plasma pharmacokinetics. The profiles of the first phase of plasma disapearance for the three tested antisense sequences are reported in Figure 4 . Oligo A cleared rapidly from blood, with a T 1/2 of ∼4.8 min and approximate AUC and clearance (Cl) of 114 min ng/ml and 4.4 l/kg/min respectively. To our knowledge these results constitute the first pharmacokinetic data relative to intact phosphodiesters in mouse.
The introduction of two phosphorothioate linkages (oligo 2-S-A) did not affect the pharmacokinetic profile or parameters: T 1/2 , AUC and Cl were 7.4 min, 188 min ng/ml and 2.7 l/kg/min respectively. The replacement of all phosphodiester linkages with phosphorothioate (oligo all-S-A) greatly increased AUC (3257 min ng/ml, by a factor of 29), decreased clearance (0.2 l/kg/min, by a factor of 22) and had no effect on T 1/2 (5.2 min). As a consequence of the introduction of phosphorothioate linkages, stronger plasma protein binding of oligo all-S-A may explain the discrepancy in T 1/2 between oligo 2-S-A and oligo A.
Half-lives observed in vitro are greater than those observed in vivo. As previously suggested (18) , in vivo plasma metabolism plays a minor role in overall in vivo elimination. This observation confirms the good specificity of the competitive hybridization assay and strengthens our assumption that N-1 and N-2 and, maybe, N-3 metabolites are minor constituents in the intact nucleotide pool in plasma.
CONCLUSION
This work demonstrated that the competitive hybridization assay can be easily applied to in vitro screening and pharmacokinetic studies of phosphodiester oligonucleotides and analogs in biological fluids like plasma, without the need for radiolabeling or extraction. The technique is convenient and can be optimized quickly. Only a few days are necessary to synthesize the sense target and tracer oligonucleotide sequences. We are able to perform >100 assays in a single day. The method could easily be developed further using an automated workstation. This assay will undoubtedly constitute a useful tool for pharmacokinetic studies of modified antisense sequences in man.
